Tjalling Bosse

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5689260/publications.pdf

Version: 2024-02-01

135 papers	12,488 citations	36303 51 h-index	27406 106 g-index
140 all docs	140 docs citations	140 times ranked	11472 citing authors

#	Article	IF	Citations
1	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. International Journal of Gynecological Pathology, 2022, 41, 12-19.	1.4	10
2	Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer. International Journal of Gynecological Pathology, 2022, 41, 220-226.	1.4	27
3	Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-Risk Endometrial Cancer. International Journal of Gynecological Pathology, 2022, 41, 227-234.	1.4	18
4	Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecologic Oncology, 2022, 164, 221-230.	1.4	11
5	Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecologic Oncology, 2022, 164, 577-586.	1.4	54
6	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
7	Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	19
8	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. Journal of Pathology, 2022, 257, 340-351.	4.5	11
9	HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva. Modern Pathology, 2022, 35, 1317-1326.	5.5	23
10	Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology. Journal of Pathology, 2022, , .	4.5	1
11	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	16.0	8
12	The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 201-212.	2.8	6
13	Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials. Gynecologic Oncology, 2022, 166, 530-537.	1.4	7
14	Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. International Journal of Gynecological Cancer, 2021, 31, 594-604.	2.5	78
15	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
16	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
17	The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110359.	3.2	54
18	Abstract IA013: Endometrial carcinomas with a mutation in DNA polymerase epsilon: A pathologist view. , 2021, , .		0

#	Article	IF	Citations
19	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
20	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. Journal of the National Cancer Institute, 2021, 113, 1212-1220.	6.3	47
21	Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. Journal of the National Cancer Institute, 2021, 113, 1203-1211.	6.3	44
22	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data metaâ€analysis. Cancer, 2021, 127, 2409-2422.	4.1	62
23	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. Cancers, 2021, 13, 2994.	3.7	23
24	Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 507-514.	2.8	4
25	Performance of a HER2 testing algorithm specific for p53â€abnormal endometrial cancer. Histopathology, 2021, 79, 533-543.	2.9	10
26	Abstract 364: The RAD51-FFPE test rapidly and reliably identifies homologous recombination deficient ovarian and endometrial carcinomas. , 2021, , .		0
27	Response to Nahshon and Lavie. Journal of the National Cancer Institute, 2021, , .	6.3	0
28	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. Cancers, 2021, 13, 4538.	3.7	8
29	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
30	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers, 2021, 13, 44.	3.7	40
31	482â€…Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer. , 2021, , .		0
32	434â€…Cytoreductive surgery in stage IV endometrial cancer: A retrospective multicentre cohort study. , 2021, , .		0
33	Integrin Î±vÎ²6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions. Cancers, 2021, 13, 6006.	3.7	1
34	Incorporation of molecular characteristics into endometrial cancer management. Histopathology, 2020, 76, 52-63.	2.9	163
35	Interpretation of somatic POLE mutations in endometrial carcinoma. Journal of Pathology, 2020, 250, 323-335.	4.5	203
36	Clinicopathological and molecular characterisation of â€˜multipleâ€classifierâ€™ endometrial carcinomas. Journal of Pathology, 2020, 250, 312-322.	4.5	205

#	Article	IF	Citations
37	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. Journal of Pathology, 2020, 250, 336-345.	4.5	164
38	Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecologic Oncology, 2020, 159, 649-656.	1.4	67
39	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	2.5	135
40	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	7.0	41
41	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	1.6	398
42	Performance of the patternâ€based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. Histopathology, 2020, 77, 92-99.	2.9	42
43	Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. Cancers, 2020, 12, 1562.	3.7	9
44	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Modern Pathology, 2020, 33, 1595-1605.	5.5	103
45	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology, 2020, 152, 102973.	4.4	31
46	28â€...Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in the combined PORTEC-1,-2 and -3 endometrial cancer trials. , 2020, , .		1
47	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
48	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers, 2020, 12, 2805.	3.7	30
49	Immunhistochemische Expression von L1CAM in endometrioiden Ovarialkarzinomen â€“ Ein neuer prognostischer Marker?. , 2020, 80, .		0
50	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. Current Oncology Reports, 2019, 21, 83.	4.0	22
51	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology, 2019, 75, 813-824.	2.9	19
52	Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1759-1767.	4.2	38
53	High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. , 2019, 7, 236.		22
54	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	1.4	74

#	Article	IF	Citations
55	Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology, 2019, 75, 128-136.	2.9	32
56	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine, 2019, 25, 838-849.	30.7	486
57	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Annals of Oncology, 2019, 30, 1232-1243.	1.2	614
58	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
59	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	3.4	141
60	MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. Frontiers in Oncology, 2019, 9, 29.	2.8	21
61	P119â€...An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. , 2019, , .		5
62	Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research, 2019, 25, 7517-7526.	7.0	34
63	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	7.0	113
64	Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes. Clinical Cancer Research, 2019, 25, 2155-2165.	7.0	19
65	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Review of Anticancer Therapy, 2019, 19, 51-60.	2.4	12
66	Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. Frontiers in Immunology, 2019, 10, 3023.	4.8	45
67	Authors' Reply. Journal of Pathology, 2018, 245, 251-251.	4.5	0
68	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. American Journal of Surgical Pathology, 2018, 42, 561-568.	3.7	214
69	Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Annals of Oncology, 2018, 29, 424-430.	1.2	71
70	Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?. Annals of Oncology, 2018, 29, 1081-1082.	1.2	3
71	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	4.5	71
72	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. Journal of Pathology, 2018, 244, 538-549.	4.5	172

#	Article	IF	Citations
73	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology, 2018, 50, 222-237.	0.6	23
74	Adjuvant Treatment for POLE Proofreading Domainâ€“Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. Clinical Cancer Research, 2018, 24, 3197-3203.	7.0	50
75	Blinded histopathological characterisation of <scp>POLE</scp> exonuclease domainâ€mutant endometrial cancers: sheep in wolf's clothing. Histopathology, 2018, 72, 248-258.	2.9	34
76	Folate receptor-Î± targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Oncotarget, 2018, 9, 791-801.	1.8	32
77	The immune cell infiltrate in the microenvironment of vulvar Paget disease. Gynecologic Oncology, 2018, 151, 453-459.	1.4	10
78	Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival. Gynecologic Oncology, 2018, 151, 196-201.	1.4	21
79	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer, 2018, 119, 1067-1074.	6.4	171
80	L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelialâ€“mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 591-598.	2.8	9
81	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. Journal of Molecular Diagnostics, 2018, 20, 600-611.	2.8	18
82	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	5.5	35
83	A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. BMC Cancer, 2018, 18, 92.	2.6	15
84	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	2.3	76
85	Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecologic Oncology, 2018, 151, 69-75.	1.4	130
86	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€”an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30
87	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. Gynecologic Oncology, 2017, 146, 327-333.	1.4	26
88	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. Modern Pathology, 2017, 30, 459-468.	5.5	53
89	Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. European Journal of Cancer, 2017, 72, 215-225.	2.8	40
90	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	4.6	102

#	Article	IF	Citations
91	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research, 2017, 23, 7232-7241.	7.0	37
92	Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. Clinical Cancer Research, 2017, 23, 6781-6789.	7.0	110
93	Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Annals of Oncology, 2017, 28, 96-102.	1.2	220
94	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. Oncotarget, 2017, 8, 25542-25551.	1.8	15
95	L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer. Oncotarget, 2017, 8, 87568-87581.	1.8	9
96	The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease. JMIR Research Protocols, 2017, 6, e178.	1.0	19
97	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget, 2016, 7, 39885-39893.	1.8	29
98	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International Journal of Gynecological Cancer, 2016, 26, 2-30.	2.5	515
99	Stathmin is a highly sensitive and specific biomarker for vulvar high-grade squamous intraepithelial lesions. Journal of Clinical Pathology, 2016, 69, 1070-1075.	2.0	10
100	Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography. Clinical Cancer Research, 2016, 22, 5506-5513.	7.0	26
101	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancerâ€"Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research, 2016, 22, 4215-4224.	7.0	535
102	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase eâ€"Mutated and Microsatellite-Instable Endometrial Cancers. JAMA Oncology, 2016, 2, 141.	7.1	2
103	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	7.0	43
104	Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?. European Journal of Cancer, 2016, 65, 139-149.	2.8	43
105	Disseminated leiomyoma cells can be identified following conventional myomectomy. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 2183-2187.	2.3	30
106	A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. Clinical Cancer Research, 2016, 22, 2929-2938.	7.0	218
107	A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Reviews Cancer, 2016, 16, 71-81.	28.4	292
108	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, 16-41.	1.2	862

#	Article	IF	Citations
109	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	7.0	132
110	Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation. International Journal of Gynecological Cancer, 2016, 26, 483-490.	2.5	12
111	Paget disease of the vulva. Critical Reviews in Oncology/Hematology, 2016, 101, 60-74.	4.4	122
112	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology, 2016, 29, 174-181.	5.5	68
113	POLE proofreading mutation, immune response and prognosis in endometrial cancer. OncoImmunology, 2016, 5, e1072675.	4.6	34
114	Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget, 2016, 7, 32144-32155.	1.8	116
115	Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. Oncotarget, 2016, 7, 26192-26205.	1.8	5
116	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	7.0	249
117	ESMOâ€“ESGOâ€“ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2015, 117, 559-581.	0.6	167
118	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer â€“ A pooled analysis of PORTEC 1 and 2 trials. European Journal of Cancer, 2015, 51, 1742-1750.	2.8	273
119	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	6.3	229
120	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. British Journal of Cancer, 2015, 113, 786-793.	6.4	20
121	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology, 2015, 28, 836-844.	5.5	343
122	Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma. Gynecologic Oncology, 2015, 139, 458-464.	1.4	20
123	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	19.2	88
124	L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. European Journal of Cancer, 2014, 50, 2602-2610.	2.8	123
125	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecologic Oncology, 2014, 133, 197-204.	1.4	70
126	Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers. PLoS ONE, 2014, 9, e93451.	2.5	39

#	Article	IF	Citations
127	Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Modern Pathology, 2013, 26, 1525-1535.	5.5	166
128	Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3Kâ€“AKT, Wnt/Î²-catenin and P53 pathway activation. Gynecologic Oncology, 2012, 126, 466-473.	1.4	60
129	Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using methylene blue. World Journal of Gastrointestinal Surgery, 2012, 4, 180.	1.5	57
130	Characterization of Expression in Mice of a Transgene Containing 3.3Âkb of the Human Lactase-Phlorizin Hydrolase (LPH) 5â€² Flanking Sequence. Digestive Diseases and Sciences, 2011, 56, 59-69.	2.3	1
131	Pretreatment with Interferon-Î³ Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of Colitis. Stem Cells, 2011, 29, 1549-1558.	3.2	287
132	GATA4 mediates gene repression in the mature mouse small intestine through interactions with friend of GATA (FOG) cofactors. Developmental Biology, 2008, 322, 179-189.	2.0	34
133	Gata4 and Hnf1Î± are partially required for the expression of specific intestinal genes during development. American Journal of Physiology - Renal Physiology, 2007, 292, G1302-G1314.	3.4	27
134	Hepatocyte nuclear factor-1Î± is required for expression but dispensable for histone acetylation of the lactase-phlorizin hydrolase gene in vivo. American Journal of Physiology - Renal Physiology, 2006, 290, G1016-G1024.	3.4	27
135	Gata4 Is Essential for the Maintenance of Jejunal-Ileal Identities in the Adult Mouse Small Intestine. Molecular and Cellular Biology, 2006, 26, 9060-9070.	2.3	118